Novel Score Predicts Weight Loss With Semaglutide in T2D

TOPLINE: Patients with both type 2 diabetes (T2D) and obesity, who have a lower diabetes severity, as characterized by the individualized metabolic surgery (IMS) scoring system, achieve better weight loss outcomes with semaglutide. METHODOLOGY: Prior studies indicate that semaglutide leads to inferior weight loss outcomes in patients with obesity who have T2D vs those without

Read more

This website is using cookies to improve the user-friendliness. You agree by using the website further.

Privacy policy
Skip to content